Showing results (61-70 of 75) with videos related to
Sort By:
Pageof 8
Cancers|June 2, 2021
Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic TargetsChiara Romani, Eliana Bignotti, Davide Mattavelli, et al.Journal of Experimental & Clinical Cancer Research : CR|May 10, 2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsRenata A Tassi, Paola Todeschini, Eric R Siegel, et al.Gynecologic Oncology|November 30, 2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitroStefania Bellone, Eliana Bignotti, Silvia Lonardi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Oxford Classic-defined EMT risk stratification of High Grade Serous Ovarian cancer for guiding treatment decisionsLena Rai, Antonella Ravaggi, Eliana Bignotti, et al.Gynecologic Oncology|November 8, 2024
Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancerStephanie W Vrede, Willem Jan Van Weelden, Johan Bulten, et al.Cancers|October 23, 2021
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational StudyDaniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, et al.American Journal of Obstetrics and Gynecology|May 21, 2021
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancerWillem Jan van Weelden, Roy I Lalisang, Johan Bulten, et al.Cancers|June 19, 2024
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial CarcinomaMaartje M W Luijten, Willem Jan van Weelden, Roy I Lalisang, et al.Proceedings of the National Academy of Sciences of the United States of America|January 30, 2013
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinomaSiming Zhao, Murim Choi, John D Overton, et al.Proceedings of the National Academy of Sciences of the United States of America|December 26, 2018
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitorsCharles Li, Elena Bonazzoli, Stefania Bellone, et al.Pageof 8